Investor Presentation Full Year 2021

11 Investor presentation Full year 2021 Novo Nordisk increased market share in the fast-growing US GLP-1 diabetes segment US GLP-1 NBRx market share NBRX share 80% 59.2% 60% 40% 20% 0% Jan 2021 Ozempic® Novo NordiskⓇ US GLP-1 TRX market share TRX share Class growth ~30% 60% 53.4% 50.1% 63.9% 40% 44.9% 34.5% 20% 12.7% 43.7% 35.1% 11.1% 6.3% 7.2% 0% Jan 2022 Jan Jan 2021 2022 RybelsusⓇ dulaglutide NN GLP-1 - VictozaⓇ Source: IQVIA Xponent, Weekly (ending 7 January 2022) Each data points represents a rolling four-week average NBRX: New-to-brand prescriptions; TRX: Total prescriptions; NN: Novo Nordisk Note: Class growth calculated as Q4 2020 vs Q4 2021

View entire presentation